### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

9-05-06

Applicant(s): Boyle, William

Serial No.:

10/762,159

Group Art Unit No.:

1647

Filed:

January 20, 2004

Examiner: Deberry, Regina M.

Docket No.:

Osteoprotegerin

A-378CIP2C5

#### INFORMATION DISCLOSURE STATEMENT

Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicant submits a copy of each of the references listed on the attached supplemental PTO-1449 Modified form for consideration by the Examiner.

Applicant makes no determination of relevancy with respect to the references submitted herewith and requests the Examiner to make an independent determination of relevance and/or materiality of the references.

Applicant, by the undersigned attorney/agent, certifies that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Robert B. Winter

Attorney/Agent for Applicant(s) Registration No.: 34,458

Phone: (805) 447-2425 Date: August 31, 2006

Please send all future correspondence to: U.S. Patent Operations/RBW Dept. 4300, M/S 28-2-C AMGEN INC. One Amgen Center Drive

#### **EXPRESS MAIL CERTIFICATE**

"Express	Mail	label	numi	er:

EL 732825581 US

Date of Deposit:

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the dat

		Sheet 1 Of	1_
Modified Form PTO-1449	Atty. Docket No.	Serial No.	
19-5	A-3782C5	10/762,159	
OLIST OF REFERENCES CITED BY APPLICANT	Applicant		
20101010000	Boyle, Willi	am	
(Use several sheets if necessary)	Filing Date	Group	
AUG 3 1 2006 (Use several sneets if necessary)	01-20-2004	1 1647	

## **U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						
	A4						

### **FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-	TRANSL	ATION
						CLASS	YES	NO
	B1	WO 94/21670	Sep 29, 1994	PCT				
	B2							
_	В3							
	B4							

# OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

C1	Garcia et al., "Transgenic Mice Expressing High Levels of Soluble TNF-R1 Fusion Protein and Protected from Lethal Septic Shock and Cerebral Malaria, and are Highly Sensitive to <i>Listeria Monocytogens</i> and <i>Leishmania Major</i> Infections", <i>European Journal of Immunology</i> , 25, 2401-2407 (1995).
C2	Himmler et al., "Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein", <i>DNA and Cell Biology</i> , 9(10), 705-715 (1990).
СЗ	
C4	
C5	
C6	
C7	
C8	
C9	
C10	

EXAMINER:	Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.